Abstract:

Objective To evaluate the short-term efficacy and safety of intensity modulated radiation therapy(IMRT) plus concomitant and adjuvant temozolomide (TMZ) in patients with  malignant gliomas and to provide basis for selection of clinical therapy program．Methods Forty-six postoperative patients with malignant gliomas confirmed by pathology were randomly divided into combined therapy group(n=22,IMRT+TMZ) and radiotherapy group(n=24,IMRT alone).All the patients were followed up for 12-31 months,and the median follow-up time was 19 months.The median progression-free survival,1-year survival rate and the incidence of adverse reactions  were observed.Results All the patients were carried out according to the plan.The median progression-free survival was 10 months in combined therapy group and 7.6 months in radiotherapy group;the 1-year survival rates were 86.36% and 58.33%（P<0.05）,respectively.The main adverse reactions in two  groups were myelosuppression and gastrointestinal reactions of gradeⅠ-Ⅱ,there was no significant difference between two groups（P>0.05）,and  the patients could tolerate well.Conclusion The combination of IMRT and TMZ can achieve much better short-term efficacy than IMRT alone,and the adverse reactions are little,which is a safe and effective method for postoperative maglignant glioma.

Key words: malignant glioma；intensity modulated radiation therapy;temozolomide;median progression-free survival;1-year survival rate；safety